Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving transferase
Reexamination Certificate
2001-04-18
2004-12-14
Leary, Louise N. (Department: 1654)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving transferase
C435S004000, C435S964000
Reexamination Certificate
active
06830897
ABSTRACT:
BACKGROUND OF THE INVENTION
Toxicity of drug candidates accounts for a significant portion of attrition during exploratory development. Following development and commercialization, therapeutic agents exhibiting adverse reactions are less competitive and may ultimately fail in the market place. Implementing a Discovery screen to weed out compounds with potential toxicity early would enable all Discovery candidates entering development to achieve a higher survival rate. Following development, the selected drugs would be more likely to enjoy a competitive advantage and a more favorable therapeutic index.
One common mode of toxicity is the formation of electrophilic reactive metabolites, which manifest their toxicity by covalent binding to nucleophilic groups present in vital cellular proteins and nucleic acids (1-2). Although not all toxicological manifestations are attributable to reactive metabolites, a significant body of literature suggests that inadequate detoxification of chemically reactive metabolites formed as a result of drug bioactivation is a pathogenic mechanism for tissue necrosis (3-4), carcinogenicity (5), teratogenicity (6) and immune mediated toxicity (7).
REFERENCES
1. Nelson, S. D. (1982) Metabolic activation and drug toxicity.
J. Med. Chem.
25, 753-65.
2. Jollow, D. J., Kocsis, J., Snyder, R., Vainio H. (1977):
Biological Reactive Intermediates.
New York, Plenum Press.
3. Pirmohamed, M., Madden, S. and Park, B. K. (1996) Idiosyncratic drug reactions.
Clin. Pharmacokinet
31, 215-230.
4. Prescott, L. F. (1983) Reactive metabolites as a cause of hepatotoxicity.
Int. J. Clin. Pharm.
3, 437-441.
5. Guengerich, F. P. (1992) Metabolic activation of carcinogens.
Pharmacol. Ther.
54, 17-61.
6. Juchau, M. R., Lee, Q. P., Fantel, A. G. (1992) Xenobiotic biotransformation/bioactivation in organogenesis-stage conceptal issues: implications for embryotoxicity and teratogenesis.
Drug Metab. Rev.
24, 195-238.
7. Hess, D. A. and Rieder, M. J. (1997) The role of reactive drug metabolites in immune-mediated adverse drug reactions.
Ann Pharmacother.
31, 1378-1387.
8. Chasseaud, L. F. (1977): In Arias, I. M., Jakoby, W. B. (eds), Glutathione: Metabolism and Function, p. 77. New York, Raven Press.
9. Baillie, T. A., Davis, M. R. (1993) Mass spectrometry in the analysis of glutathione conjugates.
Biol. Mass Spectrom.
22, 319-325.
10. Janiszewski, J, Schneider, R. P., Hoffmaster, K., Swyden, M., Wells, D., Fouda, H. G. (1997) Automated Sample Preparation Using Membrane Microtiter Extraction For Bioanalytical Mass Spectrometry.
Rapid Comm. Mass Spectrom.
11, 9.
11. Dahlin, D. C., Miwa, G. T., Lu, A. Y. H. and Nelson, S. D. (1984) N-acetyl-p-benzoquinone imine: a cytochrome P450-mediated oxidation product of acetaminophen.
Proc. Natl. Acad. Sci. U. S. A.
81, 1327-1331.
12. Williams, D. P., Pirmahamed, M., Naisbift, D. J., Maggs, J. L. and Park, B. K. (1997) Neutrophil cytoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis.
J. Pharmacol. Exp. Ther.
283, 1375-1382.
13. Madden, Stephen; Maggs, James L.; Park, B. Kevin. (1996) Bioactivation of carbamazepine in the rat in vivo. Evidence for the formation of reactive arene oxide(s).
Drug Metab. Dispos.
24(4), 469-79.
14. Ju, C,; Uetrecht, J. P. (1998) Oxidation of a metabolite of indomethacin (desmethyldeschlorobenzoylindomethacin) to reactive intermediates by activated neutrophils, hypochlorous acid, and the myeloperoxidase system.
Drug Metab. Dispos.
26(7), 676-680.
15. Schiller, Claus Dieter; Gescher, Andreas; Jheeta, Parmjit. (1991) Mechanism of toxicity of the antimelanoma drug 4-hydroxyanisole in mouse hepatocytes.
Eur. J. Cancer
27(8), 1017-22.
16. Thompson, David C.; Perera, Kumar; London, Robert. (1995) Quinone Methide Formation from Para Isomers of Methylphenol (Cresol), Ethylphenol, and Isopropylphenol: Relationship to Toxicity.
Chem. Res. Toxicol.
8(1), 55-60.
17. Tang, Wei; Abbot, Frank S. (1996) Characterization of thiol-conjugate metabolites of 2-propylpent-4-enoic acid (4-ene VPA), a toxic metabolite of valproic acid, by electrospray tandem mass spectrometry.
J. Mass Spectrom.
31(8), 926-936.
18. Roy, Deodutta; Snodgrass, Wayne R. (1990) Covalent binding of phenytoin to protein and modulation of phenytoin metabolism by thiols in A/J mouse liver microsomes.
J. Pharmacol Exp. Ther.
252(3), 895-900.
19. Kassahun, Kelem; Hu, Pei; Grillo, Mark P.; Davis, Margaret R.; Jin, Lixia; Baillie, Thomas A. (1994) Metabolic activation of unsaturated derivatives of valproic acid. Identification of novel glutathione adducts formed through coenzyme A-dependent and independent processes.
Chem.-Biol. Interact
90(3), 253-75.
20. Mays, Dennis C.; Pawluck, Lew J.; Apseloff, Glen; Davis, W. Bruce; She, Zhi-Wu; Sagone, Arthur L.; Gerber, Nicholas. (1995) Metabolism of phenytoin and covalent binding of reactive intermediates in activated human neutrophils.
Biochem. Pharmacol.
50(3), 367-80.
SUMMARY OF THE INVENTION
This invention provides a method for identifying drug candidates which produce reactive metabolites which comprises:
(a) incubating said drug candidates with a microsomal drug metabolizing enzyme system in the presence of glutathione and;
(b) detecting glutathione conjugates formed in step (a).
This invention further provides a method for identifying drug candidates which produce reactive metabolites which is a high throughput method.
This invention further provides a method for identifying drug candidates which produce reactive metabolites wherein said drug metabolizing enzyme system is a human liver system.
This invention also provides a method for identifying drug candidates which produce reactive metabolites which comprises: incubating said drug candidates with a microsomal drug metabolizing enzyme system in the presence of glutathione and detecting glutathione conjugates by tandem mass spectometry.
DETAILED DESCRIPTION OF THE INVENTION
This invention provides a high throughput method of identifying candidates with the potential to produce reactive metabolites. It exploits one of the natural mechanisms for eliminating reactive intermediates: conjugation with glutathione. Through its nucleophilic sulfhydryl group, glutathione protects vital cellular constituents against chemically reactive species which bind to the reactive electrophilic moiety, to form stable S-substituted adducts (8). The detoxification of the acetaminophen electrophilic metabolite by glutathione is one of the classic examples of that protection.
A universal analytical method for detecting glutathione conjugates, which are generated by in vitro incubation with human liver microsomal drug metabolizing enzyme systems and with glutathione, will identify compounds that undergo bioactiviation to reactive metabolites. This analytical method utilizes tandem mass spectrometry. During collision induced dissociation, all glutathione adducts undergo the neutral loss of the pyroglutamic acid moiety (129 Da). The diagnostic neutral loss of 129 Da allows the specific detection of any glutathione conjugates that have been generated via metabolic activation followed by conjugation (9).
The method of this invention is reliable, rapid, simple and amenable to high throughput automation. The incubation step can easily be automated following the heated block
96
well incubation method developed by J. Janiszewski. The sample preparation and extraction step is automated using Quadra 96 SPE (10). The analytical step is particularly simple requiring no compound specific optimization. Although we have utilized chromatography with 7-minute runtime, the specificity of the assay suggests that a runtime of 1 minute per sample is feasible. Consequently, throughput of more than 1000 compounds a day can be attained by utilizing the dual column switching system.
The method will detect most toxic compounds whose toxicity is mediated by reactive metabolites generated by bioactivation with drug metabolizing oxidative P450 systems. It will not detect reactive metabolites that do not form stable adducts with glutathione (su
Avery Michael J.
Chen Weichao G.
Fouda Hassan G.
Benson Gregg C.
Leary Louise N.
Pfizer Inc.
Ranney Kathleen A.
Richardson Peter C.
LandOfFree
High throughput screen for reducing drug candidate attrition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with High throughput screen for reducing drug candidate attrition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and High throughput screen for reducing drug candidate attrition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3309281